摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(aminomethyl)-2'-deoxyuridine | 70465-55-3

中文名称
——
中文别名
——
英文名称
5-(aminomethyl)-2'-deoxyuridine
英文别名
5-amino-2'-O-deoxythymidine;α-amino-thymidine;alpha-Aminothymidine;5-(aminomethyl)-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
5-(aminomethyl)-2'-deoxyuridine化学式
CAS
70465-55-3
化学式
C10H15N3O5
mdl
——
分子量
257.246
InChiKey
XOTMMXUBXHCRGI-XLPZGREQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.499±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -2.1
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    125
  • 氢给体数:
    4
  • 氢受体数:
    6

SDS

SDS:1940522502b9a9da98b9c4a75f839165
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(aminomethyl)-2'-deoxyuridine 、 6-(p-bromobenzoylamino)caproic acid N-hydroxysuccinimide ester 以 N,N-二甲基甲酰胺 为溶剂, 以41%的产率得到5-{N-[caproyl-6-(p-bromobenzamine)]aminomethyl}-2'-O-deoxythymidine
    参考文献:
    名称:
    Synthesis of a New Analog of Thymidine forIn VivoNon-radioactive Labeling of DNA
    摘要:
    The introduction of 6-(p-bromobenzoylamino)caproyl radical in the methyl group of 2'-O-deoxythymidine is described. In vivo incorporation of this nucleoside to DNA was determined using a monoclonal antibody that recognized the radical.
    DOI:
    10.1080/15257779908041663
  • 作为产物:
    描述:
    5-羟甲基脱氧尿苷吡啶ammonium hydroxide 、 TEA 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 反应 66.0h, 生成 5-(aminomethyl)-2'-deoxyuridine
    参考文献:
    名称:
    含有5-(苯硫甲基)-2'-脱氧尿苷:5-(2'-脱氧尿苷基)甲基自由基的特定光不稳定前体的寡聚脱氧核苷酸的合成和紫外光解。
    摘要:
    标题外环基(2)是通过光化学裂解5-(苯硫基甲基)-2'-脱氧尿苷(8)而产生的。后者的硫代核苷(8)通过使用亚磷酰胺化学方法自动进行DNA合成成功地掺入了DNA寡聚物中。在有氧条件下,含有8个寡核苷酸的紫外线暴露会引起特定的基础病变。在详细的NMR和质谱分析的基础上,已分离并进一步表征了光产物。
    DOI:
    10.1021/ol005643y
点击查看最新优质反应信息

文献信息

  • [EN] 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING<br/>[FR] 5-MÉTHOXY-NUCLÉOTIDES À TERMINAISON RAPIDEMENT PHOTOCLIVABLE NON BLOQUÉS EN 3'OH ET PROCÉDÉS DE SÉQUENÇAGE D'ACIDE NUCLÉIQUE
    申请人:LASERGEN INC
    公开号:WO2013040257A1
    公开(公告)日:2013-03-21
    The present invention relates generally to 3'-OH unblocked nucleotides and nucleosides labeled and unlabeled with 5-methoxy-substituted nitrobenzyl-based photocleavable terminating groups for use in methods and systems related to DNA and RNA sequencing and analysis. These compounds may be used as reversible terminators as they exhibit fast nucleotide incorporation kinetics, single-base termination, high nucleotide selectivity, and rapid terminating group cleavage that results in a naturally occurring nucleotide.
    本发明通常涉及用于DNA和RNA测序和分析方法及系统中的3'-OH未阻断核苷酸和核苷的标记和未标记的5-甲氧基取代硝基苯基光致裂解终止基团。这些化合物可用作可逆终止剂,因为它们表现出快速的核苷酸结合动力学、单碱基终止、高核苷酸选择性和快速的终止基团裂解,导致自然发生的核苷酸。
  • Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA)
    申请人:UNIVERSITY OF MASSACHUSETTS
    公开号:US20170035837A1
    公开(公告)日:2017-02-09
    The invention provides compositions and methods for reducing one or more symptoms of disease by administering compositions comprising SipA. The invention's compositions and methods are particularly advantageous in reducing symptoms of diseases that are associated with overexpression of P-gp and/or p53. The invention's compositions and methods are useful in reducing cancer symptom and/or cancer multidrug resistance (MDR). The invention provides a method for reducing one or more symptoms of cancer in a mammalian subject in need thereof, comprising administering to said subject a composition comprising purified SipA. In one embodiment, said SipA is operably conjugated to a nanoparticle. In another embodiment, said cancer comprises cancer cells resistant to at least one cytotoxin.
    该发明提供了通过给予含有SipA的组合物来减轻疾病的一个或多个症状的组合物和方法。该发明的组合物和方法在减轻与P-gp和/或p53过表达相关的疾病症状方面特别有优势。该发明的组合物和方法在减轻癌症症状和/或癌症多药耐药性(MDR)方面非常有用。该发明提供了一种用于减轻哺乳动物受试者中的一个或多个癌症症状的方法,包括向所述受试者给予包含纯化SipA的组合物。在一个实施例中,所述SipA与纳米颗粒可操作地结合。在另一个实施例中,所述癌症包括对至少一种细胞毒素具有抗性的癌细胞。
  • Synthesis and biological activities of 5-(hydroxymethyl, azidomethyl, or aminomethyl)-2'-deoxyuridine and related 5'-substituted analogs
    作者:George T. Shiau、Raymond F. Schinazi、Ming S. Chen、William H. Prusoff
    DOI:10.1021/jm00176a005
    日期:1980.2
    hydrogenation of the azides 9, 10, 14, and 15 gave the corresponding amines 16, 2, 6, and 7, respectively. Compounds 1, 2, 10, and 16 inhibited the growth of murine Sarcoma 180 and L1210 in culture, and the activity of 2 was prevented by 2'-deoxypyrimidine nucleosides but not by purine nucleosides. The replication of herpes simplex virus type 1 (HSV-1) was strongly inhibited only by 1 and 10. Studies on the
    5-(叠氮甲基)-2′-脱氧尿苷(10)的合成已通过两种独立的方法完成。首先涉及5-(羟甲基)-2'-脱氧尿苷的甲苯磺酸化(1),以提供两种单-和二甲苯基核苷的混合物,将其转化为相应的5-(叠氮甲基)(10),5-(叠氮甲基) 2′-脱氧尿苷的-5′-叠氮基(14)和5-(羟甲基)-5′-叠氮基(15)衍生物。第二种方法更具选择性,需要形成中间体5-(溴甲基)-3',5'-二-O-乙酰基-2'-脱氧尿苷(8),然后用叠氮化锂和溴化取代溴基。脱乙酰。叠氮化物9、10、14和15的催化氢化分别得到相应的胺16、2、6和7。化合物1、2、10和16抑制了培养物中鼠肉瘤180和L1210的生长,2'的活性被2'-脱氧嘧啶核苷阻止,但嘌呤核苷阻止。1型单纯疱疹病毒(HSV-1)的复制仅受到1和10的强烈抑制。对各种胸苷类似物与HSV-1编码的嘧啶脱氧核糖核苷激酶结合的研究表明1和10对这种酶具有良好的亲和力。
  • Tissue reactive compounds and compositions and uses thereof
    申请人:Angiotech International AG
    公开号:US20040219214A1
    公开(公告)日:2004-11-04
    A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.
    一种组合物包括一种合成聚合物,可选地存在药物,并且该聚合物包括多个活性基团。这些多个活性基团与动物组织上存在的功能性反应,因此在将聚合物注射到组织中时,聚合物与组织结合。或者,这些多个活性基团与非生物表面上存在的功能性反应,聚合物将与该表面结合,例如增加表面的润滑性。当组合物中存在药物时,药物将被传递到聚合物附着的部位。
  • Soft tissue implants and anti-scarring agents
    申请人:Hunter L. William
    公开号:US20050142162A1
    公开(公告)日:2005-06-30
    Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
    软组织植入物(例如乳房、胸肌、下巴、面部、唇部和鼻部植入物)与抗瘢痕剂结合使用,以抑制动物体内植入物放置时可能发生的瘢痕形成。
查看更多